{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:26:29Z","timestamp":1786119989839,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/inf.0b013e318224fb14","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T16:12:08Z","timestamp":1308067928000},"page":"e203-e208","source":"Crossref","is-referenced-by-count":10,"title":["Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine"],"prefix":"10.1097","volume":"30","author":[{"given":"Philip C. S.","family":"de Whalley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic F.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Banner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Diggle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-33-20210202","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States.","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R2-33-20210202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R3-33-20210202","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"R4-33-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R5-33-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae Type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R6-33-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e3181f728fd","article-title":"Persistence of immunity following a booster dose of a Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.","volume":"30","author":"Khatami","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R7-33-20210202","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial.","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R8-33-20210202","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/CVI.00279-08","article-title":"Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.","volume":"15","author":"Trotter","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"R9-33-20210202","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R10-33-20210202","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.","volume":"43","author":"Snape","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R11-33-20210202","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1016\/j.vaccine.2009.05.047","article-title":"Investigation of serum bactericidal activity in childhood and adolescence 3\u20136 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.","volume":"27","author":"Sakou","year":"2009","journal-title":"Vaccine"},{"key":"R12-33-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","article-title":"Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.","volume":"193","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"key":"R13-33-20210202","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2006-01-009282","article-title":"CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.","volume":"108","author":"Kelly","year":"2006","journal-title":"Blood"},{"key":"R14-33-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.","volume":"336","author":"Snape","year":"2008","journal-title":"Br Med J"},{"key":"R15-33-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"issue":"suppl 2","key":"R16-33-20210202","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"R17-33-20210202","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/JCM.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardised enzyme-linked immunosorbent assay.","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"key":"R18-33-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/INF.0b013e3180cc2c25","article-title":"Reconsideration of the use of meningococcal polysaccharide vaccine.","volume":"26","author":"Granoff","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R19-33-20210202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.2.2.2611","article-title":"Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.","volume":"2","author":"Trotter","year":"2006","journal-title":"Hum Vaccin"},{"key":"R20-33-20210202","doi-asserted-by":"crossref","first-page":"a1139","DOI":"10.1136\/bmj.a1139","article-title":"Meningococcal C booster not recommended by evidence.","volume":"337","author":"Thomas","year":"2008","journal-title":"Br Med J"},{"key":"R21-33-20210202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/adc.2010.192070","article-title":"Adolescent immunisation: the next big thing?","volume":"96","author":"Finn","year":"2011","journal-title":"Arch Dis Child"},{"key":"R22-33-20210202","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/adc.2010.196667","article-title":"Immunisation of adolescents in the UK.","volume":"96","author":"Kale","year":"2011","journal-title":"Arch Dis Child"},{"issue":"ACS-3","key":"R23-33-20210202","first-page":"1","article-title":"Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations: an advisory committee statement.","volume":"35","author":"Immunization","year":"2009","journal-title":"Can Commun Dis Rep"},{"key":"R24-33-20210202","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.","volume":"25","author":"De Wals","year":"2007","journal-title":"Vaccine"},{"key":"R25-33-20210202","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines\u2014Advisory Committee on Immunization Practices (ACIP), 2010.","year":"2011","journal-title":"Morbid Mortal Wkly Rep"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201111000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:30:56Z","timestamp":1786044656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201111000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e318224fb14","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}